Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Drugs in R&D · 2024
DOI: 10.1007/s40268-024-00481-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs in R&D, 2024. Verfasst von Mark T Reding und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Polyethylene Glycols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.
Abstract (Originalsprache)
Damoctocog alfa pegol (BAY 94-9027, Jivi®), is a site-specifically PEGylated, extended half-life recombinant factor VIII (FVIII) that is approved in several European and non-European countries for on-demand treatment and prophylaxis of bleeding in previously treated patients aged ≥ 12 years with hemophilia A. Reliable measurements can be obtained using most one-stage and chromogenic FVIII assays over a wide concentration range. The efficacy, safety and pharmacokinetics (PK) of damoctocog alfa pegol have been studied extensively in the PROTECT VIII clinical trials, and its long-term safety and effectiveness profile is continuing to build through observational and interventional real-world studies. The PK of damoctocog alfa pegol was shown to be improved as compared with that of sucrose-formulated rFVIII (rFVIII-FS, Kogenate®), and was also demonstrated to be non-inferior to and, for some variables, more favorable than rFVIII-Fc fusion protein, efmoroctocog alfa (Elocta®; NCT03364998), rurioctocog alfa pegol (BAX 855, Adynovate®/Adynovi®; NCT04015492), and antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM, Advate®; NCT02483208). Damoctocog alfa pegol was generally well tolerated and none of the patients in any of the clinical trials, including the PROTECT VIII clinical program, HEM-POWR, or ongoing single-center studies, developed FVIII inhibitors. Efficacy for perioperative hemostasis has been demonstrated. Low bleeding rates were achieved across the studies, with twice weekly, every 5-day and every 7-day prophylaxis offering patients ≥ 12 years and their clinicians the chance to tailor treatment to individual needs and lifestyles, while maintaining long-term protection from bleeds and their consequences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
- National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel.
- The Amalia Biron Thrombosis Research Institute, Tel Aviv University, Tel Aviv, Israel.
- Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy.
- Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA.
- Bayer AG, Berlin, Germany.
Förderung
- Bayer
Zitieren
APA
Reding, M. T., Lalezari, S., Kenet, G., Di Minno, G., Ducore, J., Solms, A., Shah, A., Holme, P. A., Poulsen, L. H., Meijer, K., Simpson, M., & Mancuso, M. E. (2024). Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review. Drugs in R&D. https://doi.org/10.1007/s40268-024-00481-7
Vancouver
Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, et al. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review. Drugs in R&D. 2024. doi:10.1007/s40268-024-00481-7
BibTeX
@article{Reding2024,
author = {Reding, Mark T and Lalezari, Shadan and Kenet, Gili and Di Minno, Giovanni and Ducore, Jonathan and Solms, Alexander and Shah, Anita and Holme, Pål André and Poulsen, Lone H and Meijer, Karina and Simpson, Mindy and Mancuso, Maria Elisa},
title = {Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review},
journal = {Drugs in R&D},
year = {2024},
doi = {10.1007/s40268-024-00481-7}
}
EUVIMED